Skip to search formSkip to main contentSkip to account menu

fimasartan

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Biphenyl CompoundsPyrimidinesTetrazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
Background and Objectives Angiotensin II (Ang II) has been suggested to accelerate vascular senescence, however the molecular… 
2019
2019
Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
2019
2019
Fimasartan versus perindopril with and without diuretics in the treatment of elderly patients with essential hypertension (Fimasartan in the Senior Subjects (FITNESS)): study protocol for a…
BackgroundHypertension is an important risk factor for cardiovascular disease, even in the elderly. Fimasartan is a new non… 
2017
2017
Pharmacological Profiles of a Highly Potent and Long-Acting Angiotensin II Receptor Antagonist, Fimasartan, in Rats and Dogs after Oral Administration.
The pharmacological profile of fimasartan, [2-n-butyl-5-dimethylamino-thiocarbonyl-methyl-6-methyl-3-{[2-(1H-tetrazole-5-yl… 
2017
2017
Decreased potency of fimasartan in liver cirrhosis was quantified using mixed-effects analysis
Fimasartan is a nonpeptide angiotensin II receptor blocker. In a previous study that compared the pharmacokinetics (PK) of… 
2016
2016
Pharmacokinetic drug interaction study using fimasartan and rosuvastatin in healthy volunteers.
OBJECTIVE This study evaluated the possible pharmacokinetic interactions between rosuvastatin and fimasartan, an angiotensin II… 
2016
2016
Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension
AbstractAngiotensin receptor blockers may be an appropriate first-line agent for postmenopausal women with hypertension because… 
2014
2014
Cardioprotective Effect of Fimasartan, a New Angiotensin Receptor Blocker, in a Porcine Model of Acute Myocardial Infarction
Cardioprotective effect of fimasartan, a new angiotensin receptor blocker (ARB), was evaluated in a porcine model of acute… 
2013
2013
A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension
A population pharmacokinetic (PK) model of fimasartan, a selective angiotensin II receptor antagonist, was developed and… 
2011
2011
Effect of age on the pharmacokinetics of fimasartan (BR-A-657)
Objectives: The aim of this study was to compare the pharmacokinetics (PK) and safety of fimasartan (BR-A-657), an angiotensin II… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)